BIRC5 and cancer: Inhibition of PLK1 leads to cellular G2/M blockade, inhibition of proliferation, and downregulation of Survivin expression to promote apoptosis, making it possible to use PLK1 inhibitors as a potential therapeutic tool to treat cancer [55].